Maplight Therapeutics, INC 8-K filings

MapLight Therapeutics announced a $150 million private placement and positive Phase 2 trial results for its schizophrenia drug candidate, ML-007C-MA, extending its cash runway through 2028.

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting its primary endpoint and showing a favorable safety profile.

MapLight Therapeutics stockholders re-elected three directors and ratified the appointment of RSM US LLP as auditors.

MapLight Therapeutics announces the immediate separation of its CFO, Vishwas Setia, due to a human resources violation, appointing Jonathan Gillis as interim CFO.

MapLight Therapeutics reported Q1 2026 financial results, highlighting strong clinical trial momentum and a cash runway through 2027, with key data readouts expected mid-August 2026.

MapLight Therapeutics announced its Q4 and full year 2025 financial results, highlighted by a strong cash position, progress in multiple Phase 2 trials, and pipeline expansion.

MapLight Therapeutics announced an update to its Phase 2 clinical trial timelines for ML-007C-MA and ML-004, with topline results now expected in Q3 2026, alongside a strong cash position of approximately $450 million as of December 31, 2025.

MapLight Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical pipeline, including significant progress in its CNS disorder programs and a strengthened financial position.

MapLight Therapeutics successfully completed its initial public offering and a concurrent private placement, raising $296.3 million in gross proceeds.